Meredith James, HT, PMP, Joins Flagship Biosciences as Vice President of Operations

July 18, 2019 – Flagship Biosciences, the advanced tissue data services company, today announced the addition of Meredith James, HT, PMP, to its executive team as Vice President of Operations. Ms. James brings a wealth of experience gained in over 20 years in drug development. In her new role, Ms. James is responsible for ensuring […]

Read More

Flagship Biosciences Announces Biocom Membership

April 3, 2019 – Flagship Biosciences, the advanced tissue data services company, today announced its membership in Biocom, the association representing the California life science industry. A Flagship representative will also serve on the Biocom Artificial Intelligence (AI) Committee. “Flagship is pleased to be part of Biocom’s member network and its AI Committee,” said Trevor […]

Read More

Flagship Biosciences Now Provides Tissue Data Services Via Scientist.com

April 1, 2019 – Flagship Biosciences, an advanced tissue data services company, today announced a new distribution channel for its services on Scientist.com, the world’s largest marketplace for outsourced scientific services. “Flagship is excited to work with Scientist.com to offer our informative contextual tissue data methods that eliminate variability associated with manual tissue analysis,” said […]

Read More

Indivumed Partners with Flagship Biosciences

Hamburg, Germany and Westminster, Colorado, USA, March 28, 2019 — Indivumed and Flagship Biosciences, Inc. are pleased to announce a partnership to expand their broad tissue-based biomarker development capabilities, as well as their clinical services to support advanced oncology diagnostics. Under the terms of the agreement, the companies will offer a comprehensive set of services […]

Read More

Flagship named Company of the Year by CIOReview

November 13, 2018 – CIOReview has named Flagship Biosciences “Company of the Year,” as part of the publication’s 2018 20 Most Promising Pharma & Life Sciences Tech Solution Providers industry review. “The ease of leveraging Flagship’s powerful solution is yet another massive differentiator of the company. Clients need not have to change their existing workflows, […]

Read More

GEN Features Flagship Solutions, cTA Platform

November 8, 2018 – Flagship’s precision medicine solutions and cTA® platform are featured in a recent GEN article, Precision Biomarkers and Medicines Go Global, summarizing highlights from the recent Clinical Biomarkers and World CDx conference in Boston. Dr. Joseph Krueger, Flagship Chief Science Officer, presented Flagship’s approach at the conference. Flagship’s cTA platform can help […]

Read More

Flagship Presents AI Solutions at SITC

November 7, 2018 – Flagship Biosciences will present its artificial intelligence (AI) driven immunotherapy solutions at the SITC annual conference, November 9-10, 2018, in Washington DC. Flagship will present a poster, “Using Artificial Intelligence to Predict Response to Immunotherapy,” (P90) at the Washington Convention Center, Hall E, on Friday, Nov. 9 and Saturday, Nov. 10. […]

Read More

Flagship Presents at Pathology Visions 2018

November 4, 2018 – Flagship Biosciences will present its artificial intelligence (AI) driven pathology solutions at the Digital Pathology Association’s 2018 Pathology Visions conference, November 4 – 6, 2018, in San Diego, CA. Learn more and download the poster here: Pathology AI (Artificial Intelligence)

Read More

Flagship Recognized Among 10 Best Technology Solution Providers of 2018

October 31, 2018 – Flagship Biosciences is honored to be named by Industry Era Magazine as one of the 10 Best Technology Solution Providers of 2018. The Industry Era Magazine article, Connecting Patients with Life-saving Drugs, notes Flagship’s ground-breaking approach that integrates multiple technologies, including its proprietary cTA platform, with a multidisciplinary team to deliver […]

Read More

Predicine and Flagship Biosciences Partner to Support Global Biomarker Development

Predicine and Flagship Biosciences are excited to announce a strategic venture to provide complimentary and comprehensive biomarker profiling to empower clinical trials in the immuno-oncology (IO) space.

Read More